Get the Stockscreener App
222.00
0.05%
0.11
After Hours:
222.00
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $222.00, with a volume of 722.14K.
It is up +0.05% in the last 24 hours and down -6.17% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$221.89
Open:
$221.08
24h Volume:
722.14K
Relative Volume:
0.52
Market Cap:
$32.02B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
21.40
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
-1.33%
1M Performance:
-6.17%
6M Performance:
-1.90%
1Y Performance:
-16.95%
1-Day Range:
$220.13
$223.22
1-Week Range:
$220.00
$227.90
52-Week Range:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
222.00 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
405.18 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.82 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.47 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.70 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
ResMed stock trades at USD 221.89 after RBC target hike - AD HOC NEWS
ResMed stock heads into the open after September 24 data - AD HOC NEWS
Will ResMed (ASX:RMD) Keep Taking Share in Sleep Apnoea? - Kalkine Media
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed CEO Farrell: Every Hour of CPAP Use Cuts Healthcare Costs 7% - finance.biggo.com
What Is ResMed Signalling With Its Share Repurchase (ASX:RMD)? - Kalkine Media
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed stock reports 10 percent fiscal revenue growth - AD HOC NEWS
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
ResMed Inc. $RMD Shares Sold by Baird Financial Group Inc. - MarketBeat
ResMed stock slips 0.73 percent ahead of the open - AD HOC NEWS
ResMed stock targets 12 to 14 percent EPS growth - AD HOC NEWS
ResMed stock heads into the open after a 0.2 percent gain - AD HOC NEWS
How Is ResMed Reshaping What It Owns (ASX:RMD)? - Kalkine Media
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand - MarketBeat
ResMed stock holds gains as analysts highlight sleep apnea growth - AD HOC NEWS
Weekly Recap: FY26 revenue & EPS growth and RBC upgrade, $1.5B buyback - TradingView
ResMed Inc. (RMD) Stock Analysis: A Healthcare Titan With A 10% Potential Upside - DirectorsTalk Interviews
ResMed Stock And Senior Healthcare Shares Linked To Medicare Spending Trends - simplywall.st
ResMed Inc. stock edges lower as analysts lift targets after recent results - AD HOC NEWS
ResMed stock gains on RBC upgrade and new institutional buying - AD HOC NEWS
ResMed Inc. stock gains on analyst upgrade and new investor interest - AD HOC NEWS
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures - Yahoo Finance
Nykredit A S Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Bank of America Corp DE Buys New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Shares Jump Following RBC Capital Upgrade to Outperform - TIKR.com
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like. - Barron's
ResMed stock jumps 3% on RBC Capital upgrade to Outperform - Investing.com
This Analyst Just Upgraded ResMed Stock. Here's Why. - Barchart.com
Why ResMed (RMD) Stock Is Up Today - Moomoo
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)? - Yahoo Finance
Resmed Inc Stock (RMD) Moved Up by 3.05% on Sep 15: A Full Analysis - TradingKey
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says - marketscreener.com
ResMed Price Target Raised to $262.00/Share From $244.00 by RBC Capital - Moomoo
Is This the Right Time to Retain Resmed Stock in Your Portfolio? - Yahoo Finance
ResMed upgraded at RBC Capital Markets on Q4 positives - Seeking Alpha
RBC Capital Upgrades ResMed(RMD.US) to Buy Rating, Raises Target Price to $262 - Moomoo
Resmed Inc. : RBC Raises to Outperform From S - Moomoo
ResMed Stock: Is RMD Underperforming the Healthcare Sector? - finance.yahoo.com
ResMed Inc. (RMD) Stock Analysis: Exploring 12.90% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed Stock Slides 9.2% Over 9 Straight Down Days - Trefis
National Pension Service Has $54.85 Million Stock Position in ResMed Inc. $RMD - MarketBeat
WINTON GROUP Ltd Makes New Investment in ResMed Inc. $RMD - MarketBeat
Why Is ResMed (NYSE:RMD) Suddenly Drawing Attention? - Kalkine Media
ResMed Stock Is Up 13% in Three Months, The Buyback Is Doing the Heavy Lifting. Here’s What It Could Be Worth Before 2027. - TIKR.com
ResMed Inc. stock extends eight-day slide as market value drops - ad-hoc-news.de
ResMed Stock Slides 8.6% Over 8 Straight Down Days - Trefis
ResMed stock heads into the open after a 0.2% dip - ad-hoc-news.de
Is ResMed (ASX:RMD) the Steadier Name in Healthcare? - Kalkine Media
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):